ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy

Lignende værker

• Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)
  af: Demeter, L. M., et al.
  Udgivet: (2000)
• Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
  af: Morse, G D, et al.
  Udgivet: (1997)
• Pharmacokinetics of Ritonavir and Delavirdine in Human Immunodeficiency Virus-Infected Patients
  af: Shelton, Mark J., et al.
  Udgivet: (2003)
• Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a Randomized, Comparative Phase III Trial
  af: Joly, Véronique, et al.
  Udgivet: (2000)
• Site-nurse initiated Adherence and Symptom Support Telephone Calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031, a substudy of ACTG 384.
  af: Robbins, Gregory K., et al.
  Udgivet: (2013)